Frequently Asked Questions
Frequently Asked Questions
Q1). What types of cancer can be treated with this technology?
A. Although the implications of our research are broad, it is not yet known how many types of cancer can be treated with the cancer killing activity technology (G.I.F.T.). Additional research will be performed on a “per cancer basis” to determine which cancers respond favorably. It is known, however, that the cancer killing activity technology is effective via invitro methods with many cell lines of cancer cells. These cell lines include:
S-180 – Sarcoma
L5178Y – Lymphoma
Meth A – Sarcoma
P815 – Mastocytoma
LL/2 – Lung Carcinoma
BW 5147.3 – T Cell Lymphoma
Hepa 1-6 – Hepatoma
KLN 205 – Squamous cell Carcinoma
EL- 4 – B- Cell Lymphoma
Q2). At what stage can cancer be treated with the cancer killing activity technology?
A. It is thought that if the cancer patient has an expected life expectancy of over four months the technology will be effective. However, at this time it is not known at what stage most cancers can be treated with this technology. Further clinical trials will be performed to establish precise cancer stage treatment protocols.
Q3). How many people are thought to be cancer resistant in the world?
A. It is estimated that from 15% – 40% of the world’s population are cancer resistant from the age of 18 to 40. After the age of 40 the percent of cancer resistancy in each individual starts to diminish.
B. It is important to note that cancer resistance is not constant between the ages of 18 and 40. Resistance is at its greatest degree during the summer months and is at its lowest during the winter months. Additionally, acute stress influences the expression of cancer resistance. Therefore, these factors have to be accounted for when determining cancer resistance.
Q4). Why is the cancer killing activity not present in the winter?
A. The lack of cancer killing activity in the winter months has nothing to do with temperatures variables. Rather, it appears to be due to the reduction in the amount of non-ionic solar radiation. It is also thought that in equatorial countries the cancer killing activity is constant year round.
Q5). How many cancer killing activity donors are necessary to treat one cancer patient?
A. It will require 5 – 7 donors. The number of cancer killing white blood cells required to treat one adult cancer patient is approximately 2.0 X 10 to the 11 power cells.
Q6). What is the treatment procedure?
A. The treatment consists of a simple transfusion. Qualified donor blood will be separated through a process called apheresis. Once the necessary granulocytes are isolated, they will be transfused.
Q7). How many cancer killing white blood cell transfusions will be required to treat most cancer patients?
A. Only one transfusion is needed. If another type of primary cancer occurs, it may require another G.I.F.T. transfusion.
Q8). How long will it normally take to see a response after the G.I.F.T. treatment in most cancer patients?
A. The response is extremely rapid. Responses can be detected in as few as two weeks and as many as six weeks after the cancer killing white blood cell transfusion.
Q9). How can specific cancer resistant individuals be identified?
A. Munogenics, Inc. will provide the technology to identify specific cancer killing individuals using a blood assay test. The lab procedures, equipment and training of lab personnel will be provided by Munogenics, Inc.
Q10). What is the cost of the G.I.F.T. cancer treatment?
A. The costs will vary from country to country. The costs will be determined by the availability and accessibility to various blood banks, the thorough testing of the donor’s blood (to test for infectious agents), the hospital and clinic costs for apheresis and transfusions, etc. The cost could be from $25,000 up to $200,000 (USD), according to each global location.
Q11). What adverse events are expected with the G.I.F.T. cancer treatment?
A. The only significant adverse event that could be experienced is graft versus host disease. GVHD was NOT seen in previous animal studies, but could occur in the human clinical trials. Since the G.I.F.T. is concerned with only granulocyte cells (primarily) of the immune system and is not any way associated with the T-cell mediated response, GVHD will be greatly diminished. It is possible that GVHD may occur in 1% - 2% of the patients treated. If GVHD does occur, it can be treated without difficulty. Cancer patients will be blood type matched to the G.I.F.T. donor’s to also diminish the occurrence of GVHD.
Q12.) Will it ever be possible to eliminate the cancer killing activity donors?
A. It is thought that in the near future, Munogenics, Inc. will invent the technology to reproduce the cell line in human cancer killing activity by invitro means. If this becomes a reality, these specific cancer killing leucocytes can be preserved and frozen and sent out to various, global cancer clinics for transfusion. This would eliminate the utilization of white blood cell donors.
Q13). Is it possible that cancer resistancy could be transgrafted to individuals in the future?
A. Munogenics, Inc. is planning a “vaccine” like compound to transfer cancer resistancy to all humans. This technology could be complete in five years or less. The vaccine could be a series of several injections starting in early adulthood. This could potentially prevent most cancers in humans for most of their lives.
Q14). Is the G.I.F.T. treatment a potential cure for cancer?
A. Yes. Preliminary research has yielded unprecedented results. Dr. Cui has documented the complete eradication of prostate cancer in the laboratory. It is thought that these results will translate to major improvements in the care of, and possibly a “cure” for, many types of cancer.
